Cargando…

Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatment

BACKGROUND: Active HIV infection within the central nervous system (CNS) is confined primarily to microglia. The glial cell compartment acts as a viral reservoir behind the blood-brain barrier. It provides an additional roadblock to effective pharmacological treatment via expression of multiple drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dallas, Shannon, Block, Michelle L, Thompson, Deborah M, Bonini, Marcelo G, Ronaldson, Patrick T, Bendayan, Reina, Miller, David S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651327/ https://www.ncbi.nlm.nih.gov/pubmed/23642074 http://dx.doi.org/10.1186/1742-2094-10-58

Ejemplares similares

Evaluation of novel Saquinavir analogs for resistance mutation compatibility and potential as an HIV-Protease inhibitor drug
por: Jayaswal, Amit, et al.
Publicado: (2014)

The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines
por: Bandiera, Elisabetta, et al.
Publicado: (2016)

Short-Term Administration of HIV Protease Inhibitor Saquinavir Improves Skull Bone Healing with Enhanced Osteoclastogenesis
por: Liu, Haixia, et al.
Publicado: (2022)

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
por: Wiesmann, Frank, et al.
Publicado: (2011)

Saquinavir: From HIV to COVID-19 and Cancer Treatment
por: Pereira, Mariana, et al.
Publicado: (2022)

New-Onset Saquinavir-Induced Diabetes
por: van Zoelen, Marieke A.D., et al.
Publicado: (2013)

Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients
por: Stephan, C, et al.
Publicado: (2010)

Understanding Drug Resistance of Wild-Type and L38HL Insertion Mutant of HIV-1 C Protease to Saquinavir
por: Venkatachalam, Sankaran, et al.
Publicado: (2023)

Tratamiento con saquinavir + zalcitabina + zidovudina vs saquinavir + lamivudina + zidovudina en pacientes con SIDA sin tratamiento previo
por: Jaimes Martínez, Marcos
Publicado: (2000)

Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA
por: Bello, Martiniano, et al.
Publicado: (2020)

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers
por: Schmitt, Christophe, et al.
Publicado: (2009)

Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers
por: Jamois, Candice, et al.
Publicado: (2009)

A Case of Nephrotic Syndrome, Showing Evidence of Response to Saquinavir
por: Walters, Giles, et al.
Publicado: (2015)

Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
por: Zhang, Guanghua, et al.
Publicado: (2018)

Saquinavir-Piperine Eutectic Mixture: Preparation, Characterization, and Dissolution Profile
por: Fandaruff, Cinira, et al.
Publicado: (2023)

Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate
por: Knechten, Heribert, et al.
Publicado: (2010)

The HIV protease inhibitor Saquinavir attenuates sepsis-induced acute lung injury and promotes M2 macrophage polarization via targeting matrix metalloproteinase-9
por: Tong, Yao, et al.
Publicado: (2021)

Drug Resistance Mechanism of M46I-Mutation-Induced Saquinavir Resistance in HIV-1 Protease Using Molecular Dynamics Simulation and Binding Energy Calculation
por: Rana, Nilottam, et al.
Publicado: (2022)

Enhancement of saquinavir absorption and accumulation through the formation of solid drug nanoparticles
por: Kigen, Gabriel, et al.
Publicado: (2018)

Repurposing Saquinavir for Host-Directed Therapy to Control Mycobacterium Tuberculosis Infection
por: Pires, David, et al.
Publicado: (2021)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
por: Tommasi, Chiara, et al.
Publicado: (2011)

Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4(+) immune cells
por: Yang, Sidi, et al.
Publicado: (2013)

The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naïve and pre-treated but protease inhibitor (PI)- naïve hiv-infected patients
por: Knechten, H, et al.
Publicado: (2011)

Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells
por: Pereira, Mariana, et al.
Publicado: (2022)

Defective Hydrophobic Sliding Mechanism and Active Site Expansion in HIV-1 Protease Drug Resistant Variant Gly48Thr/Leu89Met: Mechanisms for the Loss of Saquinavir Binding Potency
por: Goldfarb, Nathan E., et al.
Publicado: (2014)

Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients
por: Julio, Montaner SG, et al.
Publicado: (2006)

Synthesis of biogenic gold nano conjugate for increased efficacy and sustained drug release profile of saquinavir
por: Kesarkar, Rohan, et al.
Publicado: (2014)

Enhanced intestinal lymphatic absorption of saquinavir through supersaturated self-microemulsifying drug delivery systems
por: Jo, Kanghee, et al.
Publicado: (2020)

The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro
por: Adamo, Riccardo, et al.
Publicado: (2013)

Chronic Apocynin Treatment Attenuates Beta Amyloid Plaque Size and Microglial Number in hAPP(751)(SL) Mice
por: Lull, Melinda E., et al.
Publicado: (2011)

Loss of NF-κB p50 function synergistically augments microglial priming in the middle-aged brain
por: Taetzsch, Thomas, et al.
Publicado: (2019)

Specific Increase in MDR1 Mediated Drug-Efflux in Human Brain Endothelial Cells following Co-Exposure to HIV-1 and Saquinavir
por: Roy, Upal, et al.
Publicado: (2013)

Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats
por: Li, Jiapeng, et al.
Publicado: (2016)

Antiretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro
por: Brilhante, Raimunda Sâmia Nogueira, et al.
Publicado: (2015)

Liposomal Delivery of Saquinavir to Macrophages Overcomes Cathepsin Blockade by Mycobacterium tuberculosis and Helps Control the Phagosomal Replicative Niches
por: Pires, David, et al.
Publicado: (2023)

Nanosized Cubosomal Thermogelling Dispersion Loaded with Saquinavir Mesylate to Improve Its Bioavailability: Preparation, Optimization, in vitro and in vivo Evaluation
por: Hosny, Khaled M
Publicado: (2020)

Clinical PET Imaging of Microglial Activation: Implications for Microglial Therapeutics in Alzheimer’s Disease
por: Shen, Zhiwei, et al.
Publicado: (2018)

Microglial VPS35 deficiency regulates microglial polarization and decreases ischemic stroke-induced damage in the cortex
por: Ye, Shi-Yang, et al.
Publicado: (2019)

Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects
por: Wan, Li, et al.
Publicado: (2006)

Regulation of ABC Drug Efflux Transporters in Human T-Cells Exposed to an HIV Pseudotype
por: Whyte-Allman, Sana-Kay, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_me0h52osh84op68tofdvrovlc8